Definium Therapeutics, Inc.
NASDAQ:DFTX · NASDAQ Global Select
-$0.41 today
Vol 1.68M · Avg 2.67M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:DFTX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$237.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.49, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $527.0K -83.3% | $3.2M | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 +100.0% | -$527.0K +83.3% | -$3.2M | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $117.7M +80.2% | $65.3M +33.4% | $49.0M +35.4% | $36.2M +4.0% | $34.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $48.6M +26.0% | $38.6M -7.5% | $41.7M +38.4% | $30.2M -48.9% | $59.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $166.3M +60.9% | $103.4M +14.0% | $90.7M +36.7% | $66.3M -29.3% | $93.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $527.0K -83.3% | $3.2M -0.6% | $3.2M +21.6% | $2.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$178.3M -68.4% | -$105.9M -14.4% | -$92.6M -77.6% | -$52.1M +42.9% | -$91.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$166.3M -60.0% | -$103.9M -10.7% | -$93.9M -41.5% | -$66.3M +29.3% | -$93.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $11.0M -5.2% | $11.6M +107.0% | $5.6M +273.5% | $1.5M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $5.5M +140.1% | $2.3M +148.2% | $920.0K -38.5% | $1.5M +316.4% | $359.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$17.5M -267.1% | -$4.8M -155.3% | -$1.9M -119.6% | $9.5M +2912.7% | -$339.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$183.8M -69.1% | -$108.7M -13.5% | -$95.7M -68.6% | -$56.8M +39.7% | -$94.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 +100.0% | -$1.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$183.8M -69.1% | -$108.7M -13.5% | -$95.7M -68.6% | -$56.8M +39.0% | -$93.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 -33.8% | -$2 +36.9% | -$2 -59.5% | -$2 +55.0% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 -1273.3% | -$0 +93.9% | -$2 -59.5% | -$2 +55.0% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $89.3M +26.8% | $70.5M +79.9% | $39.2M +26.9% | $30.9M +12.7% | $27.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $89.3M -87.3% | $704.6M +1699.4% | $39.2M +26.9% | $30.9M +12.7% | $27.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.61B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.40B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.91B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.60B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.46B
Savara Inc.
NASDAQ:SVRA
$1.11B
Xencor, Inc.
NASDAQ:XNCR
$937.92M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$605.61M
Rezolute, Inc.
NASDAQ:RZLT
$481.46M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does DFTX generate?
Definium Therapeutics, Inc. (DFTX) reported $0.00 of revenue in fiscal 2025.
Is DFTX profitable?
Definium Therapeutics, Inc. (DFTX) reported -$183,793,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.